Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) saw a significant decline in short interest in October. As of October 15th, there was short interest totaling 74,500 shares, a decline of 44.7% from the September 30th total of 134,800 shares. Currently, 1.2% of the shares of the company are sold short. Based on an average daily volume of 163,600 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily volume of 163,600 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.2% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Traws Pharma stock. Vestal Point Capital LP increased its stake in Traws Pharma, Inc. (NASDAQ:TRAW) by 133.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 175,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Vestal Point Capital LP owned approximately 3.28% of Traws Pharma worth $402,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.95% of the company’s stock.

Traws Pharma Stock Performance

Shares of TRAW stock opened at $2.64 on Friday. The company has a market capitalization of $18.82 million, a PE ratio of 0.03 and a beta of 1.69. Traws Pharma has a 52-week low of $0.97 and a 52-week high of $19.44. The business’s fifty day moving average is $2.14 and its 200 day moving average is $1.74.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Thursday, August 14th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($8.75) by $8.64. Traws Pharma had a negative return on equity of 1,812.48% and a net margin of 3,028.25%.The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $0.06 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Traws Pharma in a research note on Thursday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.